The House Goes Long On Drones
Client Alert | 1 min read | 09.20.22
Last week, the House passed the Drone Infrastructure Inspection Grant Act, which establishes programs within the Department of Transportation (DOT) to support the use of small unmanned aircraft systems (sUAS) when inspecting, repairing, or constructing a variety of types of infrastructure, including roads, electric grids, water, and other critical infrastructure.
Specifically, the legislation authorizes DOT to award up to $100 million over two years in grants to state, tribal and local governments to support their purchase and use of sUAS to increase efficiency, reduce costs, improve worker safety, and reduce carbon emissions when carrying out infrastructure inspections, repairs, and construction. In addition to the customary flowdown requirements that accompany grant funding, the infrastructure inspection grants will include mandatory country of origin provisions, requiring grant recipients to use U.S.-manufactured sUAS made by companies not subject to Chinese influence or control.
The legislation also authorizes a separate $100 million pool of funding for DOT to use for grants to educational institutions to support student training and education in the use of drones and related technologies.
The bill, which passed the House by a 308-110 vote, now proceeds to the Senate. A companion bill was introduced in the Senate on August 8 and has been referred to the Committee on Commerce, Science, and Transportation for consideration. Both bills have significant support from industry leaders and local government groups.
Contacts
Senior Counsel
She/Her/Hers
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
